Mutation Analysis of ABL Kinase Domain in Tunisian Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors (SOHO 2026) - Sep 1, 2026 - Abstract #CML-899; Location: LEVEL 3, HALL B3; "Other-generation ABL TKIs, such as dasatinib, nilotinib, bosutinib, and ponatinib, have been developed to help overcome imatinib resistance. Our results highlight that ABL KD mutations are uncommon in Tunisian patients with CML. Delineation of the landscape of resistance is mandatory for early detection of emerging mutant clones, which could help in decision-making for alternative treatment. ABL: Abelson murine leukemia viral oncogene homolog 1, BCR: breakpoint cluster region."
Biomarker • Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
|
|
Rim Frikha MD PhD; Amina El Aoud MS; Hassen Kamoun MD
|